Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.

Thoren KL, Pianko MJ, Maakaroun Y, Landgren CO, Ramanathan LV.

J Appl Lab Med. 2019 Mar;3(5):857-863. doi: 10.1373/jalm.2018.026476. Epub 2018 May 31.

PMID:
31639760
2.

Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.

Landau H, Lahoud O, Devlin S, Lendvai N, Chung DJ, Dogan A, Landgren CO, Giralt S, Hassoun H.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30530-0. doi: 10.1016/j.bbmt.2019.08.016. [Epub ahead of print]

PMID:
31446197
3.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.

PMID:
30408566
4.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.

5.

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ.

Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6. Review.

6.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM.

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30. No abstract available.

7.

Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.

Salem DA, Korde N, Venzon DJ, Liewehr DJ, Maric I, Calvo KR, Braylan R, Tembhare PR, Yuan CM, Landgren CO, Stetler-Stevenson M.

Leuk Lymphoma. 2018 Jan;59(1):178-186. doi: 10.1080/10428194.2017.1321746. Epub 2017 May 25.

8.

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.

Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO.

Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. No abstract available.

PMID:
28482750

Supplemental Content

Loading ...
Support Center